Evidence map›Paper›PMID 38276639›Full record

ArticleMarine drugs2023

In Silico Analysis of USP7 Inhibitors Based on Building QSAR Models and Fragment Design for Screening Marine Compound Libraries.

Huiting Tan, Chenying Li, Tianli Lai, Lianxiang Luo

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Huiting TanThe First Clinical College, Guangdong Medical University, Zhanjiang 524023, China.
Chenying LiThe First Clinical College, Guangdong Medical University, Zhanjiang 524023, China.
Tianli LaiThe First Clinical College, Guangdong Medical University, Zhanjiang 524023, China.
Lianxiang LuoThe Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China.ORCID 0000-0002-3391-9713
Guangdong Medical College · CN

Funding

The Key Discipline Construction Project of Guangdong Medical University (4SG23004G, 2022KTSCX043)The Science and technology program of Guangdong Province (2023A1515010850)
6 · The paper itself

Abstract

USP7 is highly expressed in a variety of tumors and is thought to play a major role in cancer development. However, there are no drugs available to target USP7, so there is a need to develop new USP7 inhibitors. In this study, AutoQSAR, multiple linear regression, and Naive Bayesian models were constructed using 543 compounds and used to analyze marine compounds. After selecting 240 small molecules for molecular docking with Maestro, MOE, and GOLD, better small molecules than the positive compound P217564 were screened. The molecular structure of "1, 2-dibromobenzene" was optimized to improve the binding effect of the protein, and 10 optimized compounds in ADMET performed well during the screening process. To study the dynamic combination of protein-ligand effect consistency with static molecular docking, 100ns molecular dynamics simulations of candidate compound 1008-1, reference compound P217564, and negative-positive GNE2917 were conducted. The results of molecular docking and molecular dynamics simulation analysis showed that compound 1008-1 maintained a stable conformation with the target protein. Thus, the comprehensive analysis suggests that compound 1008-1 could provide new possibilities for USP7 covalent inhibitor candidates.

Indexed as

NeoplasmsQuantitative Structure-Activity RelationshipBayes TheoremHumansMolecular Docking SimulationMolecular Dynamics SimulationUbiquitin-Specific Peptidase 7Ubiquitin-Specific Peptidase 7USP7 protein, humanmarine natural compoundsmolecular dockingmolecular dynamicsQSARscaffold hoppingUSP7virtual screening

Identifiers

PMID38276639
PMCPMC10817464
OpenAlexW4389952107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.